Poniard Plans 2009 NDA For “New Generation” Platinum-Based Chemotherapy Picoplatin
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes ongoing studies will support three-pronged safety and efficacy benefit showing the oncologic overcomes platinum resistance, is neuropathy sparing and combines well with other treatments.
You may also be interested in...
Poniard’s Picoplatin Shows Good Tox Profile In Early ASCO Abstracts
Data from Phase III lung cancer trial due in third quarter.
Poniard’s Picoplatin Shows Good Tox Profile In Early ASCO Abstracts
Data from Phase III lung cancer trial due in third quarter.
Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.